Modus Therapeutics, a spinout of Karolinska Institute and Uppsala University developing therapies for sickle cell disease, has closed a SKr32m ($3.5m) funding round backed by KDev Investments, the investment arm of commercialisation firm Karolinska Development. The round also included Östersjöstiftelsen, the Swedish state-owned Foundation for Baltic and East European Studies, and Praktikerinvest, the corporate venturing arm of healthcare company Praktikertjänst. Modus Therapeutics will use the capital to support a phase 2 clinical trial for which it is currently recruiting patients…